B
Bishal Gyawali
Researcher at Queen's University
Publications - 261
Citations - 16176
Bishal Gyawali is an academic researcher from Queen's University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 25, co-authored 194 publications receiving 10845 citations. Previous affiliations of Bishal Gyawali include State University of New York System & Kathmandu.
Papers
More filters
Journal ArticleDOI
Burden of Diabetes and Prediabetes in Nepal: A Systematic Review and Meta-Analysis
TL;DR: The prevalence of prediabetes and diabetes was high in Nepal, while its awareness, treatment, and control were low, and the findings call for urgent nationwide public health action in Nepal.
Journal ArticleDOI
Combating non-communicable diseases: potentials and challenges for community health workers in a digital age, a narrative review of the literature.
Shiva Raj Mishra,Charilaos Lygidakis,Dinesh Neupane,Bishal Gyawali,Jean Paul Uwizihiwe,Salim S. Virani,Per Kallestrup,J. Jaime Miranda +7 more
TL;DR: The evidence is reviewed and how the digitalization affects the CHWs programmes for tackling non-communicable diseases in low- and middle-income countries (LMICs) is discussed, identifying three benefits and three challenges of digitalization.
Journal ArticleDOI
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
Bishal Gyawali,E.G.E. de Vries,Urania Dafni,T. Amaral,Jorge Barriuso,Jan Bogaerts,Antonio Calles,Giuseppe Curigliano,Giuseppe Curigliano,Carlos Gomez-Roca,Barbara Kiesewetter,Sjoukje F. Oosting,Antonio Passaro,Georgios Pentheroudakis,Martine Piccart,Felipe Roitberg,Josep Tabernero,N. Tarazona,Dario Trapani,Ruth Wester,G. Zarkavelis,Christoph C. Zielinski,Panagiota Zygoura,Nathan I. Cherny +23 more
TL;DR: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit from cancer medicines reported in clinical trials.
Journal ArticleDOI
Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice
Ravi B. Parikh,Matthew D. Galsky,Bishal Gyawali,Bishal Gyawali,Fauzia Riaz,Tara L. Kaufmann,Aaron B. Cohen,Blythe J.S. Adamson,Cary P. Gross,Neal J. Meropol,Ronac Mamtani +10 more
TL;DR: Real‐world patterns of CPI initiation near the end of life among individuals with metastatic urothelial cell carcinoma are described.
Journal ArticleDOI
Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment.
Isabelle R Weir,G.D. Marshall,G.D. Marshall,Jeffrey I. Schneider,Jeffrey I. Schneider,Jason A. Sherer,Emily M. Lord,Bishal Gyawali,Michael K. Paasche-Orlow,Emelia J. Benjamin,Ludovic Trinquart +10 more
TL;DR: Comparing interpretation of cancer RCTs with time-to-event outcomes when the reported treatment effect measure is the hazard ratio (HR), difference in restricted mean survival times (RMSTD), or both (HR+RMSTD) and the prevalence of misinterpretation of the HR is compared.